Article Information
History
- December 14, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yuichi Kojimaa,
- Sho Nakakuboa,*,
- Keisuke Kamadaa,b,c,
- Yu Yamashitaa,d,
- Nozomu Takeia,
- Junichi Nakamuraa,
- Munehiro Matsumotoa,
- Hiroshi Horiia,
- Kazuki Satoa,
- Hideki Shimaa,
- Masaru Suzukia and
- Satoshi Konnoa
- aDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan
- bDepartment of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo, Japan
- cDepartment of Epidemiology and Clinical Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo, Japan
- dDepartment of Respiratory Medicine 1, Obihiro Kosei General Hospital, Obihiro, Japan
- ↵*Corresponding Author Sho Nakakubo, Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan., E-mail: shonakakubo{at}pop.med.hokudai.ac.jp, Tel: +81-11-706-5911
Posted December 14, 2021.
Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study
